

Insert new claims, as follows:

D2
86. (NEW) The transdermal delivery system of claim 84 wherein said acrylic-based polymers include a C₄-C₁₂ alkyl acrylate.

87. (NEW) The transdermal delivery system of claim 86 wherein said acrylic-based polymers include a C₁-C₄ alkyl acrylate hardening monomer.

mm727
88. (NEW) The transdermal delivery system of claim 87 wherein said acrylic-based polymers include a functionalizing monomer.

89. (NEW) The transdermal delivery system of claim 88 wherein said acrylic-based polymers include a cross-linking agent.

90. (NEW) The transdermal delivery system of claim 84 wherein said at least one of said one or more drugs has a molecular weight of less than about 300 MW.

91. (NEW) The transdermal delivery system of claim 84 including from about 3% to 35% of said therapeutically effective amount of one or more drugs.

Sub E3
92. (NEW) A transdermal delivery system consisting essentially of a blend of:

(a) an acrylic-based polymer; and

(b) a therapeutically effective amount of a drug having a low molecular weight and being a liquid at or about room temperatures, wherein said system is substantially free of solvents selected from the group consisting of water and liquids having a normal boiling point

(i) below processing temperature and

(ii) equal to or greater than the normal boiling points of the low molecular weight drugs,

CAN
HMT
WATER?

E3
Cmt
Dg
Cmt

Application No.: 08/883,075

Docket No.: BERTEK 3.0-025

whereby said transdermal drug delivery system, subsequent to processing, is free of said solvents.
